Impact of the presence of cardiac comorbidities on hazard ratio of death within 180 days
| Cardiac comorbidity | Patients (n) | Deaths No (%) | HR1 (95% CI) | p Value | HR2 (95% CI) | p Value | HR3 (95% CI) | p Value |
| None | ||||||||
| No angiography | 1771 | 258 (14.6) | 1.00 | 1.00 | 1.00 | |||
| Angiography only | 1274 | 49 (3.8) | 0.25 (0.18 to 0.34) | 0.59 (0.42 to 0.83) | 0.002 | 0.61 (0.43 to 0.860) | 0.004 | |
| With intervention | 2486 | 53 (2.1) | 0.14 (0.10 to 0.19) | 0.37 (0.26 to 0.52) | 0.41 (0.29 to 0.59) | |||
| One or more comorbidity | ||||||||
| No angiography | 2525 | 519 (20.6) | 1.00 | 1.00 | 1.00 | |||
| Angiography only | 1098 | 99 (9.0) | 0.41 (0.33 to 0.51) | 0.56 (0.49 to 0.77) | 0.59 (0.47 to 0.75) | |||
| With intervention | 1642 | 73 (4.4) | 0.20 (0.16 to 0.25) | 0.29 (0.25 to 0.43) | 0.33 (0.25 to 0.43) |
p Value <0.001 for all comparisons unless stated.
HR1, hazard ratio after univariate analysis; HR2, hazard ratio adjusted for age, sex, Asian ethnicity, current smoking, admitting consultant, admission to cardiac facility, deprivation in highest quartile, propensity score; HR3, hazard ratio adjusted as for HR2 plus the following: previous angina, previous myocardial infarction, heart failure, chronic obstructive pulmonary disease, chronic renal failure, peripheral vascular disease, cerebrovascular disease, hypertension, diabetes, treated hyperlipidaemia, discharge drugs: angiotensin converting enzyme inhibitor, β blocker, aspirin, clopidogrel, statin.